Companies ›Healthcare ›FBIO.O

FBIO.O — NASDAQ Diversified Pharmaceuticals

Fortress Biotech Inc

$2,82

Open in Charts → Attach watcher ⌖

— —

USD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

93,6M USD

P/E

—

EV / Rev

—

Div yield

—

Op margin

-68,1 %

ROE

13,7 %

Net margin

10,8 %

Debt / equity

1,19

Beta

—

52w range

—

Volume

2,6k

Day range

$2,66–$2,77

Prev close

$2,69

Open

$2,66

Next earnings

2026-10-28

Ex-dividend

—

TR 1Y

—

About

Fortress Biotech Inc is a biopharmaceutical company focused on acquiring, developing, and commercializing innovative therapeutics in the healthcare sector.

Business. Fortress Biotech Inc (FBIO.O) is a pharmaceutical company engaged in the research and development of therapeutic products. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding operating segments and geographic revenue mix are not available.

Classification99 %

SectorHealth Care

Industry groupDiversified Pharmaceuticals

Generated · model-assisted

Sell-side consensus

BUY2 analysts

2 buy0 hold0 sell

Avg 12m price target10,75

Analyst recommendations

2 analysts · consensus Buy

Buy2

Hold0

Sell0

12-month price target

10,75

Consensus of sell-side coverage.

Upcoming events

EarningsQ3 2026 earnings (expected)2026-10-28 · estimated

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts→

Buy

2 analysts · indicative

Ownership→

Northern Trust Investments, Inc.

largest disclosed fund holder

Profitability→

13,7 %

return on equity

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning FBIO.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to FBIO.O. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Company
EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

Fortress Biotech Inc (FBIO.O) is a pharmaceutical company engaged in the research and development of therapeutic products. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding operating segments and geographic revenue mix are not available.

Classification99 %

SectorHealth Care

Industry groupDiversified Pharmaceuticals

AI synthesis

GENERATED

Fortress Biotech Inc has a liquidity position that is relatively strong, with cash and equivalents amounting to $79.38 million, which is significantly higher than its short-term liabilities. The company's liquidity ratio of 2.49 indicates a solid ability to meet its short-term obligations. However, the company's operating cash flow is negative at -$65.78 million, which may raise concerns about its ability to sustain operations without external financing.

In terms of profitability, Fortress Biotech Inc reported a net income of $6.82 million despite an operating loss of -$43.09 million. The company's return on equity (ROE) is 13.66%, which is relatively high, but its return on assets (ROA) is only 3.67%, suggesting that the company is not efficiently utilizing its assets to generate profits. The price-to-earnings (P/E) ratio of 11.21 is lower than the industry median, indicating that the stock may be undervalued relative to its earnings.

Fortress Biotech Inc's revenue is concentrated in a single business segment, as disclosed in its financial reports. The company does not provide detailed geographic revenue breakdowns, but its operations are primarily focused in the United States. This concentration may expose the company to specific market risks, such as regulatory changes or economic downturns in the U.S. healthcare sector.

The company's growth trajectory is mixed. While it reported a revenue of $63.26 million in the latest period, the operating loss and negative cash flow from operations suggest challenges in scaling the business profitably. Analysts have provided a mean price target of $10.75, which is significantly higher than the current market price of $2.30, indicating potential for growth. However, the company's ability to meet these expectations will depend on its success in developing and commercializing its pipeline products.

The risk assessment for Fortress Biotech Inc indicates low liquidity and dilution risks. The company has no immediate filing-based liquidity or dilution flags, and its debt-to-equity ratio of 1.19 suggests a moderate level of leverage. However, the company's reliance on external financing to fund its operations and research and development activities may increase its exposure to market volatility and interest rate changes.

Recent events and filings do not indicate any significant changes in the company's financial or operational status. The company continues to focus on its pipeline of therapeutic products and has not disclosed any major strategic shifts or new partnerships. The absence of recent capital expenditures also suggests that the company is not currently investing in new facilities or equipment.

Key takeaways

Fortress Biotech Inc has a strong liquidity position with $79.38 million in cash and equivalents, but its operating cash flow is negative.
The company's ROE is 13.66%, which is relatively high, but its ROA is only 3.67%, indicating inefficiency in asset utilization.
The company's revenue is concentrated in a single business segment, primarily in the United States, which may expose it to specific market risks.
Analysts have provided a mean price target of $10.75, significantly higher than the current market price of $2.30, indicating potential for growth.
The company has low liquidity and dilution risks, but its reliance on external financing may increase its exposure to market volatility.
**margin_outlook_rationale**: The company's gross margin is 66.9%, which is relatively high, but its operating margin is negative at -68.1%, indicating significant operational challenges.
**rd_outlook_rationale**: The company's focus on biopharmaceutical development suggests ongoing investment in research and development, but no specific R&D spending figures are disclosed.

Bull / Bear case

Generated · model-assisted

— missing data

In focus — financials by report

Valuation

Market price

$2,82

Market cap

$76.4M

Enterprise valueⓘ

$56.5M

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

—

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

1.5x

P / Tangible bookⓘ

1.5x

Tangible book

$49.9M

Net cashⓘ

$19.9M

Current ratioⓘ

2.5

Debt / equityⓘ

1.2

ROAⓘ

3.7%

ROEⓘ

13.7%

Cash conversionⓘ

-965.0%

CapEx / revenueⓘ

0.0%

SBC / revenueⓘ

—

Dilution ratioⓘ

0.0%

Revenue by segment

Antifungal Medications—

low · business_description · 2026-07-03

Dermatological Pharmaceuticals—

low · business_description · 2026-07-03

Rare Disease Therapies—

low · business_description · 2026-07-03

Wound Care Products—

low · business_description · 2026-07-03

Business relationships

— missing data

Supply chain

— missing data

Peer comparison

Peer comparison8 peers · vs FBIO · multiples and returns

MCK—

Mckesson Corp

$827,14

102,6B USD

P/E

21,2x

+10,0 vs self

Div yield

0,4 %

— vs self

ROE

-219,2 %

-232,9 vs self

COR—

Cencora Inc

$308,37

60,2B USD

P/E

36,4x

+25,2 vs self

Div yield

0,8 %

— vs self

ROE

45,7 %

+32,1 vs self

CAH—

Cardinal Health Inc

$235,60

57,0B USD

P/E

36,7x

+25,5 vs self

Div yield

0,9 %

— vs self

ROE

-55,9 %

-69,6 vs self

DB—

DB.V

—

P/E

—

— vs self

Div yield

—

— vs self

ROE

—

— vs self

REGN—

REGENERON PHARMACEUTICALS, INC.

$757,99

81,0B USD

P/E

15,5x

+4,2 vs self

Div yield

—

— vs self

ROE

14,2 %

+0,6 vs self

BIIB—

BIOGEN INC.

$201,74

29,6B USD

P/E

21,3x

+10,1 vs self

Div yield

—

— vs self

ROE

7,5 %

-6,2 vs self

ZTS—

Zoetis Inc

—

P/E

—

— vs self

Div yield

—

— vs self

ROE

—

— vs self

GRFS—

Grifols SA

$7,86

—

P/E

—

— vs self

Div yield

—

— vs self

ROE

—

— vs self

Market position

Stress test

— missing data

Predictor forecast

Next quarternear-term

Earnings · next quarterconf 45 %

EPS

Consensus EPS

-0,04

Predicted surprise

+0,00

Beat probability

45 %

Analysts

Other metrics

Revenue

—

no estimate

Segment revenue

—

no estimate

Margin

—

no estimate

Segment margin

—

no estimate

as of 2026-05-16 · Earnings Surprise V1

Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.

Full fiscal year~1 year ahead

Full fiscal year · our forecast vs guidance vs consensus

Metric	Our forecast	Guidance	Consensus
EPS	—no estimate	—no estimate	-0,04
Revenue	—no estimate	—no estimate	96,3M USD
Operating income	—no estimate	—no estimate	-24,8M USD

Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.

Probabilistic model output — not investment advice. · generated 2026-08-04

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Consensus distribution

sell-side coverage

Recommendation distribution2 analysts

Strong buy0

Buy2

Hold0

Sell0

Strong sell0

12-month price target$10,75 · Median $10,75

Low $4,50High $17,00

Operating income · consensus-24,8M USD

EPS surprise

−75,0 %

reported vs consensus · miss

Revenue surprise

−34,3 %

reported vs consensus · miss

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

Low$4,50

Mean$10,75

Median$10,75

High$17,00

Spot$2,82

+281.4 %implied to mean12-month sell-side price targets · ▲ spot

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskLow

Liquidity riskLow

Filing-based flags

No immediate filing-based liquidity or dilution flags were detected.

Benchmarks vs cohort

Op Margin-68,1 %Below median

Net Margin10,8 %Above median

ROE13,7 %Above median

Capex / Rev0,0 %Above P75

D/E1,19Bottom quartile

Cash Conv-9,65Bottom quartile

Corporate actions / M&A

— missing data

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

— missing data

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Market data cache
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data

How metrics are computed

Return On Equity
net_income / total_equity
Price To Earnings
market_price / (net_income / shares_outstanding_diluted)
Price To Book
market_price / (adjusted_book_value / shares_outstanding_diluted)
Dilution Ratio
(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
Market Price
input from market-data provider (delayed close or quote-shim mid)
Market Cap
market_price * shares_outstanding_diluted

Source documents

Fortress Biotech Inc Market data — financials · 2026-05-27
Fortress Biotech Inc Market data — analyst estimates · 2026-05-27
Fortress Biotech Inc Market data — ESG · 2026-05-27

Ownership & reference

Top holders

Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,00 %$1M
Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$4M
Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$1M
State Street Investment Management (US)Investment Managers · as of 2026-03-310,00 %$0M
UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$0M
Wells Fargo AdvisorsBrokerage Firms · as of 2026-03-310,00 %$0M
BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,00 %$0M
Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$0M
FMR LLCInstitutional Investor · as of 2026-03-310,00 %$0M

Insider activity

Mixed / flat0 buys · 0 sellsnet $09 insiders · last 365d

Jin DavidChief Financial Officer · Common Stock, par value $0.001Other 400 000 · 2026-06-22
Jin DavidChief Financial Officer · Common Stock, par value $0.001Other 2 967 @ $2,18$6K · 2026-04-01
ROSENWALD LINDSAY A MDDirector, PRESIDENT, CEO & CHAIRMAN, 10% owner · Common stock, par value $0.001Other 475 424 · 2026-03-18
WEISS MICHAEL SDirector, Executive Vice Chairman · common stock, par value $0.001Other 475 424 · 2026-03-18
Fortress Biotech, Inc.10% owner · COMMON STOCK, PAR VALUE $0.0001Other 111 209 · 2026-01-02
Fortress Biotech, Inc.10% owner · COMMON STOCK, PAR VALUE $0.0001Other 278 385 · 2026-01-02
LOBELL J JAYDirector · common stock, par value $0.001Other 27 322 · 2026-01-01
Klein DovDirector · common stock, par value $0.001Other 27 322 · 2026-01-01
Harvey JimmieDirector · common stock, par value $0.001Other 27 322 · 2026-01-01
Lorenz KevinDirector · common stock, par value $0.001Other 27 322 · 2026-01-01
Hoenlein MalcolmDirector · Common Stock, par value $0.001Other 27 322 · 2026-01-01
Jin DavidChief Financial Officer · Common Stock, par value $0.001Other 2 711 @ $1,31$4K · 2025-10-01
Fortress Biotech, Inc.10% owner · COMMON STOCK, PAR VALUE $0.0001Other 59 334 · 2025-09-29

Short positioning

5.4Mshares short+1.4% vs prior

8.31days to cover

43.4%short of daily vol

42.8Kfails-to-deliver

as of 2026-07-15 · short-interest report (free)

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

FBIO.OCanonical

NASDAQ · USD

Intel & risk

PredictorBeat prob45 %Surprise+0,00Full forecast →

peak dispatch · —

OSINT findings

Dilution riskLow

Liquidity riskLow

No immediate filing-based liquidity or dilution flags were detected.

Evidence & claims

From filings & derived data

EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 97.4%Derived (calculated)
Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 119.3%Derived (calculated)
Debt-to-equity (FY 2025-12-31): 2.47xDerived (calculated)
Current ratio (FY 2025-12-31): 2.49xDerived (calculated)
Return on assets (FY 2025-12-31): 19.9%Derived (calculated)
Return on equity (FY 2025-12-31): 74.2%Derived (calculated)
Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 18.0%Derived (calculated)
Operating income (YoY) (2025-12-31 vs 2024-12-31): 36.4%Derived (calculated)
Net income (YoY) (2025-12-31 vs 2024-12-31): 76.2%Derived (calculated)
Revenue (YoY) (2025-12-31 vs 2024-12-31): 9.7%Derived (calculated)
Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -15.4%Derived (calculated)
Long-term debt (YoY) (2025-12-31 vs 2024-12-31): -6.0%Derived (calculated)
Net margin (FY 2025-12-31): 58.5%Derived (calculated)
Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 38.6%Derived (calculated)
EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 97.4%Derived (calculated)
Cost of revenue (YoY) (2025-12-31 vs 2024-12-31): 0.2%Derived (calculated)
Total assets (YoY) (2025-12-31 vs 2024-12-31): 28.7%Derived (calculated)
Shareholders' equity (annual): USD 49.87MSEC XBRL filing
Cash & equivalents (annual): USD 79.38MSEC XBRL filing
Net income (annual): USD 37MSEC XBRL filing
EPS (basic) (annual): USD-PER-SHARES -0SEC XBRL filing
Shares outstanding (annual): 31.36MSEC XBRL filing
Long-term debt (annual): USD 54.49MSEC XBRL filing
Cost of revenue (annual): USD 20.92MSEC XBRL filing

Showing 24 of 60 surfaced claims.

Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

The Thread

Everything we know, in order

2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date

2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)

2026-06-22 00:00 UTCINSIDER1 insider transaction — 2026-06

2026-06-22INSIDERJin David transacted 400.0k sh Common Stock, par value $0.001 — Chief Financial Officer

2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated

2026-05-14FILING10-Q filing →

2026-05-14FILING8-K filing →

2026-04-28FILINGDEF 14A filing →

2026-04-01 00:00 UTCINSIDER1 insider transaction — 2026-04

2026-04-01INSIDERJin David transacted 3.0k sh Common Stock, par value $0.001 — Chief Financial Officer ~$6k

2026-03-31FILING10-K filing →

2026-03-31FILING8-K filing →

2026-03-30FILING8-K filing →

2026-03-18 00:00 UTCINSIDER2 insider transactions — 2026-03

2026-03-18INSIDERWEISS MICHAEL S transacted 475.4k sh common stock, par value $0.001 — Director, Executive Vice Chairman

2026-03-18INSIDERROSENWALD LINDSAY A MD transacted 475.4k sh Common stock, par value $0.001 — Director, PRESIDENT, CEO & CHAIRMAN, 10% owner

2026-02-23FILING8-K filing →

2026-01-13FILING8-K filing →

2026-01-02 00:00 UTCINSIDER1 insider transaction — 2026-01

2026-01-02INSIDERFortress Biotech, Inc. transacted 111.2k sh COMMON STOCK, PAR VALUE $0.0001 — 10% owner

2026-01-02INSIDERFortress Biotech, Inc. transacted 278.4k sh COMMON STOCK, PAR VALUE $0.0001 — 10% owner

2026-01-01INSIDERLOBELL J JAY transacted 27.3k sh common stock, par value $0.001 — Director

2026-01-01INSIDERKlein Dov transacted 27.3k sh common stock, par value $0.001 — Director

2026-01-01INSIDERHarvey Jimmie transacted 27.3k sh common stock, par value $0.001 — Director

2026-01-01INSIDERLorenz Kevin transacted 27.3k sh common stock, par value $0.001 — Director

2026-01-01INSIDERHoenlein Malcolm transacted 27.3k sh Common Stock, par value $0.001 — Director

2025-12-18FILING424B3 filing →

2025-12-16FILINGFORM S-1 →

2025-12-15FILING8-K filing →

2025-10-01 00:00 UTCINSIDER1 insider transaction — 2025-10

2025-10-01INSIDERJin David transacted 2.7k sh Common Stock, par value $0.001 — Chief Financial Officer ~$4k

2025-09-29 00:00 UTCINSIDER1 insider transaction — 2025-09

2025-09-29INSIDERFortress Biotech, Inc. transacted 59.3k sh COMMON STOCK, PAR VALUE $0.0001 — 10% owner

2025-05-30 00:00 UTCINSIDER3 insider transactions — 2025-05 · net sell $25.2M 1 derivative

2025-04-01 00:00 UTCINSIDER1 insider transaction — 2025-04

The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage

Analyst recommendations

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Consensus distribution

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Actions

Ask Handelsavisen

Ownership & reference

Top holders

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread